Dasatinib-induced renal (or chronic) thrombotic microangiopathy in a patient with chronic myeloid leukemia: A case report.

Ryan Sabour, Sohrab Kharabaf, Eric Frazier, Matthew Nguyen, Dao Le, Jonathan Zuckerman, Ramy Hanna

Abstract readCase Reports

In one paragraph

Article in SAGE open medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ryan SabourDivision of Nephrology, Hypertension and Transplant Nephrology, Department of Medicine, University of California, Irvine, CA, USA.ORCID https://orcid.org/0000-0002-7252-8221

Sohrab KharabafDivision of Nephrology, Hypertension and Transplant Nephrology, Department of Medicine, University of California, Irvine, CA, USA.ORCID https://orcid.org/0000-0002-1215-4424

Eric FrazierDivision of Nephrology, Hypertension and Transplant Nephrology, Department of Medicine, University of California, Irvine, CA, USA.ORCID https://orcid.org/0009-0005-4681-4901

Matthew NguyenDivision of Nephrology, Hypertension and Transplant Nephrology, Department of Medicine, University of California, Irvine, CA, USA.ORCID https://orcid.org/0000-0002-6517-041X

Dao LeDivision of Nephrology, Hypertension and Transplant Nephrology, Department of Medicine, University of California, Irvine, CA, USA.

Jonathan ZuckermanDepartment of Pathology and Lab Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0001-9758-2147

Ramy HannaDivision of Nephrology, Hypertension and Transplant Nephrology, Department of Medicine, University of California, Irvine, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombotic microangiopathy encompasses microvascular thrombosis, hemolytic anemia, thrombocytopenia, and end-organ damage. Secondary thrombotic microangiopathy can result from malignancies, autoimmune diseases, or treatments such as tyrosine kinase inhibitors. Dasatinib, a tyrosine kinase inhibitor used in managing chronic myeloid leukemia, has been linked to thrombotic microangiopathy. This report describes a 66-year-old female with chronic myeloid leukemia treated with dasatinib who developed renal-limited thrombotic microangiopathy. Progressive renal dysfunction found in the context of chronic kidney disease prompted extensive lab evaluation and evaluation, with a renal biopsy confirming thrombotic microangiopathy attributed to dasatinib-induced nephrotoxicity. Discontinuation of dasatinib led to a slight improvement in renal function; however, progressive decline necessitated dialysis. This case underscores the diagnostic and therapeutic challenges of dasatinib-induced thrombotic microangiopathy, emphasizing renal biopsy in diagnosis and monitoring. Individualized treatment strategies and further research should be conducted to optimize future outcomes.

Indexed as

Chronic kidney diseasechronic myeloid leukemiadasatinibmicroangiopathynephrologytyrosine kinase inhibitor

Identifiers

PMID39967609

DOI10.1177/2050313X251322621

PMCPMC11833818

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.